Neuro-Oncology Reviews
Volume
26 Number 5
15 March 2024
Home > Publications > Neuro-Oncology Reviews > Volume 26, Year 2024 > Number 5, 15 March
Kegoya Y, Otani Y, Inoue Y, Mizuta R, Higaki F, Washio K, Koizumi
S, Kurozumi K, Ishida J, Fujii K, Yamamoto N, Tanaka Y, Date
I.
Midline invasion predicts poor
prognosis in diffuse hemispheric glioma, H3 G34-mutant: an
individual participant data review.
J
Neurooncol. 2024 Mar 1. doi:
10.1007/s11060-024-04587-5. PMID:
38427132. Observational study; Review. ˍ
Pu Z, Wu Y, Zhu Z, Zhao H, Cui D.
A
new horizon for neuroscience: terahertz biotechnology in brain
research.
Neural
Regen Res. 2024 Mar 1;20(2):309-325. doi:
10.4103/NRR.NRR-D-23-00872? PMID:
38819036. Review. ˍ
Ritchey
AK
et
al., PDQ Pediatric Treatment Editorial Board.
Childhood
Ependymoma Treatment (PDQ®): Patient
Version.
PDQ
Cancer Inf Sum.
2024 Mar 1.
NCBI
Bookshelf:
NBK65742. PMID
26389185.
Review. ˍ
Ritchey
AK, et al., PDQ
Pediatric
Treatment Editorial Board.
Childhood
Medulloblastoma and Other Central Nervous System Embryonal Tumors
Treatment (PDQ®): Patient Version.
PDQ
Cancer Inf Summ.
2024 Mar 1. NCBI
Bookshelf:
NBK65964.
PMID:
26389401.
Review.
ˍ
Lee KS, Borbas B, Plaha P, Ashkan K, Jenkinson MD, Price
SJ.
Incidence and Risk Factors of
Surgical Site Infection After Cranial Surgery for Patients with
Brain Tumors: A Systematic Review and Meta-analysis.
World
Neurosurg. 2024 Mar 2:S1878-8750(24)00346-2. doi:
10.1016/j.wneu.2024.02.133. PMID:
38432506. Review; Meta-analysis˰
ˍ
Li K, Deng Z, Lei C, Ding X, Li J, Wang C.
The
Role of Oxidative Stress in Tumorigenesis and Progression.
Cells.
2024 Mar 2;13(5):441. doi:
10.3390/cells13050441. PMID:
38474405.
Review.
ˍ
Mikic N, Gentilal N, Cao F, Lok E, Wong ET, Ballo M, Glas M,
Miranda PC, Thielscher A, Korshoej AR.
Tumor-treating
fields dosimetry in glioblastoma: Insights into treatment
planning, optimization, and dose-response
relationships.
Neurooncol
Adv. 2024 Mar 2;6(1):vdae032. doi:
10.1093/noajnl/vdae032. PMID:
38560348. Review. ˍ
Agarwal A, Edgar MA, Desai A, Gupta V, Soni N, Bathla G.
Molecular
GBM versus Histopathological GBM: Radiology-Pathology-Genetic
Correlation and the New WHO 2021 Definition of Glioblastoma.
AJNR
Am J Neuroradiol. 2024 Mar 4:ajnr.A8225. doi:
10.3174/ajnr.A8225. PMID:
38438167. Case report; Review˰
ˍ
Breen WG, Aryal MP, Cao Y, Kim MM.
Integrating
multi-modal imaging in radiation treatments for
glioblastoma.
Neuro
Oncol. 2024 Mar 4;26(Supplement_1):S17-S25. doi:
10.1093/neuonc/noad187. PMID:
38437666.
Review.
ˍ
Tseng CL, Zeng KL, Mellon EA, Soltys SG, Ruschin M, Lau AZ, Lutsik
NS, Chan RW, Detsky J, Stewart J, Maralani PJ, Sahgal A.
Evolving
concepts in margin strategies and adaptive radiotherapy for
glioblastoma: A new future is on the horizon.
Neuro
Oncol. 2024 Mar 4;26(Supplement_1):S3-S16. doi:
10.1093/neuonc/noad258. PMID:
38437669.
Review.
ˍ
Xie Y, Sun G, Tao Y, Zhang W, Yang S, Zhang L, Lu Y, Du G.
Current
advances on the therapeutic potential of scutellarin: an updated
review.
Nat Prod Bioprospect. 2024 Mar 4;14(1):20.
doi:
10.1007/s13659-024-00441-3. PMID:
38436812.
Review.
ˍ
Azzarelli R, Gauthier LR, Pineda JR, Marques-Torrejon
MA.
Editorial: Tumor accommodation: the
importance of the niche in neurological tumors.
Front
Oncol. 2024 Mar 5;14:1383594. doi:
10.3389/fonc.2024.1383594. PMID:
38505590. Editorial. ˍ
Kobayashi A, Kitagawa Y, Nasser A, Wakimoto H, Yamada K, Tanaka
S.
Emerging Roles and Mechanisms of RNA
Modifications in Neurodegenerative Diseases and Glioma.
Cells.
2024 Mar 5;13(5):457. doi:
10.3390/cells13050457. PMID:
38474421.
Review.
ˍ
Nabian N, Ghalehtaki R, Zeinalizadeh M, Balaña C, Jablonska
PA.
State of the neoadjuvant therapy
for glioblastoma multiforme-Where do we stand?
Neurooncol
Adv. 2024 Mar 5;6(1):vdae028. doi:
10.1093/noajnl/vdae028. PMID:
38560349. Review. ˍ
Stockdill ML, King A, Johnson M, Karim Z, Cooper D, Armstrong
TS.
The relationship between social
determinants of health and neurocognitive and mood-related
symptoms in the primary brain tumor population: A systematic
review.
Neurooncol
Pract. 2024 Mar 5;11(3):226-239. doi:
10.1093/nop/npae016. PMID:
38737608. Review. ˍ
*Xing Y, Yasinjan F, Geng H, He M, Yang M, Gao Y, Zhang J, Zhang
L, Guo B.
A scientometric analysis of
immunotherapies for gliomas: Focus on GBM.
Asian
J Surg. 2024 Mar 5:S1015-9584(24)00400-7. doi:
10.1016/j.asjsur.2024.02.138. PMID:
38448290. Bibliometric analysis. ˍ
Lan Z, Li X, Zhang X.
Glioblastoma: An
Update in Pathology, Molecular Mechanisms and Biomarkers.
Int
J Mol Sci. 2024 Mar 6;25(5):3040. doi:
10.3390/ijms25053040. PMID:
38474286.
Review.
ˍ
*Marino N, Bedeschi M, Vaccari ME, Cambiaghi M, Tesei A.
Glitches
in the brain: the dangerous relationship between radiotherapy and
brain fog.
Front
Cell Neurosci. 2024 Mar 7;18:1328361. doi:
10.3389/fncel.2024.1328361. PMID:
38515789. Review. ˍ
Zhai W, Yu Q, Wu H.
The efficacy and
safety of novel antiepileptic drugs in treatment of epilepsy of
patients with brain tumors.
Front
Neurol. 2024 Mar 7;15:1344775. doi:
10.3389/fneur.2024.1344775. PMID:
38523608. Review. ˍ
Buchalska B, Kamińska K, Owe-Larsson M, Cudnoch-Jędrzejewska
A.
Cannabinoids in the treatment of
glioblastoma.
Pharmacol
Rep. 2024 Mar 8. doi:
10.1007/s43440-024-00580-x. PMID:
38457018. Review˰ ˍ
Fernando D, Ahmed AU, Williams BRG.
Therapeutically
targeting the unique disease landscape of pediatric high-grade
gliomas.
Front
Oncol. 2024 Mar 8;14:1347694. doi:
10.3389/fonc.2024.1347694. PMID:
38525424. Review. ˍ
*Tripathy DK, Panda LP, Biswal S, Barhwal K.
Insights
into the glioblastoma tumor microenvironment: current and emerging
therapeutic approaches.
Front
Pharmacol. 2024 Mar 8;15:1355242. doi:
10.3389/fphar.2024.1355242. PMID:
38523646. Review. ˍ
Zeng J, Deng Q, Chen Z, Yan S, Dong Q, Zhang Y, Cui Y, Li L, He Y,
Shi J.
Recent development of VEGFR
small molecule inhibitors as anticancer agents: A patent review
(2021-2023).
Bioorg
Chem. 2024 Mar 9;146:107278. doi:
10.1016/j.bioorg.2024.107278. PMID:
38484586. Review˰ ˍ
Di Ieva A.
Fractal Analysis in Clinical
Neurosciences: An Overview.
Adv
Neurobiol. 2024 Mar 10;36:261-271. doi:
10.1007/978-3-031-47606-8_13. PMID:
38468037. Review˰ ˍ
Mazarakis NK, Robinson SD, Sinha P, Koutsarnakis C, Komaitis S,
Stranjalis G, Short SC, Chumas P, Giamas G.
Management
of glioblastoma in elderly patients: A review of the
literature.
Clin
Transl Radiat Oncol. 2024 Mar 10;46:100761. doi:
10.1016/j.ctro.2024.100761. PMID:
38500668. Review. ˍ
*Galldiks N, Kaufmann TJ, Vollmuth P, Lohmann P, Smits M, Veronesi
MC, Langen KJ, Rudá R, Albert NL, Hattingen E, Law I,
Hutterer M, Soffietti R, Vogelbaum MA, Wen PY, Weller M, Tonn
JC.
Challenges, Limitations and
Pitfalls of PET and Advanced MRI in Patients with Brain Tumors - A
Report of the PET/RANO Group.
Neuro
Oncol. 2024 Mar 11:noae049. doi:
10.1093/neuonc/noae049. PMID:
38466087. Review˰ ˍ
Gupta T, Chatterjee A.
Existing and
Evolving Landscape of Medulloblastoma: Towards Optimization and
Personalization.
Diagnostics
(Basel). 2024 Mar 12;14(6):598. doi:
10.3390/diagnostics14060598. PMID:
38535019. Editorial. ˍ
*Karve AS, Desai JM, Gadgil SN, Dave N, Wise-Draper TM, Gudelsky
GA, Phoenix TN, DasGupta B, Yogendran L, Sengupta S, Plas DR,
Desai PB.
A Review of Approaches to
Potentiate the Activity of Temozolomide against Glioblastoma to
Overcome Resistance.
Int
J Mol Sci. 2024 Mar 12;25(6):3217. doi:
10.3390/ijms25063217. PMID:
38542190. Review. ˍ
Wion D.
About the incompleteness of our
models.
J
Neurooncol. 2024 Mar 12. doi:
10.1007/s11060-024-04632-3. PMID:
38472542. Perspective˰
ˍ
Zhao J, Ma X, Gao P, Han X, Zhao P, Xie F, Liu M.
Advancing
glioblastoma treatment by targeting metabolism.
Neoplasia.
2024 Mar 12;51:100985. doi:
10.1016/j.neo.2024.100985. PMID:
38479191.
Review.
ˍ
d'Amati A, Bargiacchi L, Rossi S, Carai A, Bertero L, Barresi V,
Errico ME, Buccoliero AM, Asioli S, Marucci G, Del Baldo G,
Mastronuzzi A, Miele E, D'Antonio F, Gessi M, Antonelli M, Gianno
F.
Pediatric CNS tumors and 2021 WHO
classification: what do oncologists need from pathologists?
Front
Mol Neurosci. 2024 Mar 13;17:1268038. doi:
10.3389/fnmol.2024.1268038. PMID:
38544524. Review. ˍ
Evans A, Prather KY, Battiste J, Fung KM, Dunn IF, Graffeo
CS.
Genetically Distinct Oligosarcoma
Arising from Oligodendroglioma: Systematic Review &
Illustrative Case Example.
World
Neurosurg. 2024 Mar 13:S1878-8750(24)00403-0. doi:
10.1016/j.wneu.2024.03.028. PMID:
38490447. Case report; Review˰
ˍ
Hu LS, Smits M, Kaufmann TJ, Knutsson L, Rapalino O, Galldiks N,
Sundgrene PC, Cha S.
Advanced Imaging
in the Diagnosis and Response Assessment of High-Grade Glioma: AJR
Expert Panel Narrative Review.
AJR
Am J Roentgenol. 2024 Mar 13. doi:
10.2214/AJR.23.30612. PMID:
38477525. Review˰ ˍ
Ledford H.
Deadly brain cancer shrinks
after CAR-T therapy - but for how long is unclear.
Nature.
2024 Mar 13. doi:
10.1038/d41586-024-00704-6. PMID:
38485827. Perspective. ˍ
Lim SH, Yee GT, Khang D.
Nanoparticle-Based
Combinational Strategies for Overcoming the Blood-Brain Barrier
and Blood-Tumor Barrier.
Int
J Nanomedicine. 2024 Mar 13;19:2529-2552. doi:
10.2147/IJN.S450853. PMID:
38505170. Review. ˍ
Onciul R, Brehar FM, Toader C, Covache-Busuioc RA, Glavan LA,
Bratu BG, Costin HP, Dumitrascu DI, Serban M, Ciurea
AV.
Deciphering Glioblastoma:
Fundamental and Novel Insights into the Biology and Therapeutic
Strategies of Gliomas.
Curr
Issues Mol Biol. 2024 Mar 13;46(3):2402-2443. doi:
10.3390/cimb46030153. PMID:
38534769. Review. ˍ
Palavani LB, Ferreira MY, Borges PGLB, Bandeira L, da Silva
Semione G, Almeida MV, Verly G, Polverini AD, Andreão FF,
Camerotte R, Ferreira C, Paiva W, Bertani R, Boockvar
J.
Ultrasound-Guided Resection of
High-Grade Gliomas: A Single-Arm Meta-Analysis.
World
Neurosurg. 2024 Mar 13:S1878-8750(24)00418-2. doi:
10.1016/j.wneu.2024.03.033. PMID:
38490442. Meta-analysis˰
ˍ
Yu A, Zeng J, Yu J, Cao S, Li A.
Theory
and application of TTFields in newly diagnosed glioblastoma.
CNS
Neurosci Ther. 2024 Mar 13;30(3):e14563. doi:
10.1111/cns.14563. PMID:
38481068.
Review.
ˍ
Saeed AM, Bentzen SM, Ahmad H, Pham L, Woodworth GF, Mishra
MV.
Systematic review and pooled
analysis of the impact of treatment-induced lymphopenia on
survival of glioblastoma patients.
Radiat
Oncol. 2024 Mar 14;19(1):36. doi:
10.1186/s13014-023-02393-3. PMID:
38481255.
Review;
Pooled analysis.
ˍ
*Sung SY, Song JH, Kim BH, Kwak YK, Kim KS, Yoo GS, Byun HK, Kim
YJ, Kim YS.
Evidence-based clinical
recommendations for hypofractionated radiotherapy: exploring
efficacy and safety - Part 1. Brain and head and neck.
Radiat
Oncol J. 2024 Mar 14;42(1):17-31. doi:
10.3857/roj.2023.00899. PMID:
38549381. Guidelines. ˍ
Timmermann B, Alapetite C, Dieckmann K, Kortmann RD,
Lassen-Ramshad Y, Maduro JH, Ramos Albiac M, Ricardi U, Weber
DC.
ESTRO-SIOPE guideline: Clinical
management of radiotherapy in atypical teratoid/rhabdoid tumors
(AT/Rts).
Radiother
Oncol. 2024 Mar 14:110227. doi:
10.1016/j.radonc.2024.110227. PMID:
38492671. Guidelines. ˍ
Al-Lami BS, Al-Lami BS, Al-Lami YS.
PET/CT
in comparison with PET/MRI as an imaging modality in the
management of Gliomas-A systematic review and meta analysis.
J
Med Imaging Radiat Sci. 2024 Mar
15:S1939-8654(24)00021-3. doi:
10.1016/j.jmir.2024.02.008. PMID:
38490940. Review; Meta-analysis˰
ˍ
Sener U, Islam M, Webb M, Kizilbash SH.
Antiangiogenic
exclusion rules in glioma trials: Historical perspectives and
guidance for future trial design.
Neurooncol
Adv. 2024 Mar 15;6(1):vdae039. doi:
10.1093/noajnl/vdae039. PMID:
38596714. Review. ˍ
Valerius AR, Webb MJ, Hammad N, Sener U, Malani R.
Cerebrospinal
Fluid Liquid Biopsies in the Evaluation of Adult Gliomas.
Curr
Oncol Rep. 2024 Mar 15. doi:
10.1007/s11912-024-01517-6. PMID:
38488990. Review˰ ˍ